Pharmaceuticals News and Research

RSS

Ensemble Therapeutics announces initiation of drug discovery collaboration with Alexion subsidiary

Ensemble Therapeutics, a biotechnology company developing Ensemblins, a novel class of small molecule therapeutics with the potential to modulate targets typically addressed by biologics, today announced the initiation of a drug discovery collaboration with a subsidiary of Alexion Pharmaceuticals, Inc., the global biopharmaceutical company focused on developing and commercializing life-transforming therapies for patients with life-threatening, ultra-rare disorders.

18 Jul 2013

Kolltan signs research agreement with CHOP for novel therapeutic approaches for neuroblastoma

Kolltan Pharmaceuticals, Inc., a privately held biopharmaceutical company, today announced a license and research agreement with The Children's Hospital of Philadelphia to commence a collaboration with Yaël Mossé, M.D, an internationally recognized clinician and scientist for her work studying the causes and novel therapeutic approaches for the treatment of children diagnosed with neuroblastoma.

18 Jul 2013

Quest Diagnostics completes sale of ibrutinib commercialization rights to Royalty Pharma

Quest Diagnostics Incorporated, the world's leading provider of diagnostic information services, announced today that it has completed the sale of its rights to royalties from commercialization of the drug candidate ibrutinib to Royalty Pharma, the industry leader in acquiring royalty interests in marketed and late stage biopharmaceutical products, for $485 million in cash.

From Quest Diagnostics 18 Jul 2013

Inovio's electroporation technology enhances ability of DNA therapy to stimulate blood vessel growth

Inovio Pharmaceuticals, Inc. announced today that the use of its proprietary electroporation technology significantly enhanced the ability of a DNA therapy to stimulate blood vessel growth, which may be beneficial for the treatment of critical limb ischemia and other forms of peripheral arterial disease.

18 Jul 2013

Mandate matters: Examining the relationship between the health law's employer and individual mandates

The Associated Press reports that delaying the enforcement of the employer mandate may undermine the individual mandate, too, while the National Journal reports on a study weighing which of these provisions has the most weight.

18 Jul 2013

Creating, promoting foods containing angiogenesis is the new frontier in dietary health

Creating and promoting foods that contain natural inhibitors of unhealthy angiogenesis - the formation of blood vessels that feed and promote disease, obesity and inflammation - is the "new frontier in dietary health," according to a presentation at the 2013 Institute of Food Technologists Annual Meeting & Food Expo- in Chicago.

18 Jul 2013

TSRI scientists study 3-D structure of glucagon receptor for treatment of diabetes

The study is reported on July 17, 2013, in an advance online edition of the journal Nature, alongside a British laboratory's structural study of another member of the same class of receptors-known as "class B" G protein-coupled receptors (GPCRs).

18 Jul 2013

Chemical compound from ocean microbe offers potential treatments for anthrax

A team led by William Fenical at Scripps Institution of Oceanography at UC San Diego has discovered a new chemical compound from an ocean microbe in a preliminary research finding that could one day set the stage for new treatments for anthrax and other ailments such as methicillin-resistant Staphylococcus aureus (MRSA).

18 Jul 2013

Rexahn Pharmaceuticals signs license agreement with UMB for novel drug delivery platform

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, announced today that it has signed an exclusive license agreement with the University of Maryland, Baltimore for a novel drug delivery platform, Nano-Polymer-Drug Conjugate Systems.

17 Jul 2013

Adynxx receives FDA Fast Track designation for AYX1 Injection to treat chronic pain

Adynxx, a clinical-stage pharmaceutical company developing a first-in-class platform of therapeutics to address pain at its molecular roots, announced today that the U.S. Food and Drug Administration has granted Fast Track designation to AYX1 Injection for the prevention of chronic pain.

17 Jul 2013

Spectrum Pharmaceuticals enters into agreement to acquire Talon Therapeutics

Spectrum Pharmaceuticals, Inc., a biotechnology company with fully-integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that, through a wholly-owned subsidiary, the company entered into an agreement to acquire Talon Therapeutics, Inc., a biopharmaceutical company based in South San Francisco, California, and expects to complete the acquisition within one day.

17 Jul 2013

First Edition: July 17, 2013

Today's headlines include a report about how the delay of the health law's employer mandate might undermine enforcement of the measure's individual mandate as well as news that the House will consider a bill that would put off both of these provisions.

17 Jul 2013

Sequella licenses Pfizer's exclusive worldwide rights to develop, commercialize sutezolid

Sequella, a clinical-stage pharmaceutical company commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it has licensed Pfizer Inc's exclusive worldwide rights to develop and commercialize sutezolid, a Phase 2 oxazolidinone antibiotic currently in development for the treatment of tuberculosis.

17 Jul 2013

The more you chew, the more energy you retain

Almonds may still be considered one of the highest energy food sources but it's not about how much you bite off, instead it's about how much you chew, according to a July 14 panel discussion at the 2013 Institute of Food Technologists Annual Meeting & Food Expo- held at McCormick Place.

17 Jul 2013

OncoGenex completes enrollment in OGX-427 Phase 2 trial for treatment of metastatic bladder cancer

OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.

16 Jul 2013

FDA accepts Iroko's submicron indomethacin NDA for treatment of acute pain in adults

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to scientific advancements in analgesia, announced that the U.S. Food and Drug Administration has accepted for review the New Drug Application for lower dose submicron indomethacin, a non-steroidal anti-inflammatory drug, for the proposed indication of treatment of mild to moderate acute pain in adults.

16 Jul 2013

Study identifies new therapeutic targets for Huntington's disease

A scientific study describes that GluN3A subunits of NMDA receptors that interact with glutamate —the main exciting neurotransmitter in the nervous system— are therapeutic targets against Huntington's disease.

16 Jul 2013

Furiex Pharmaceuticals enrolls patient for Phase III clinical trial of eluxadoline for treatment of diarrhea

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced completion of patient enrollment in the company's two ongoing Phase III clinical trials studying eluxadoline for the treatment of diarrhea-predominant irritable bowel syndrome, or IBS-d. Both studies met their target enrollments and Furiex expects to release top line results in the first quarter of 2014.

16 Jul 2013

USC study shows missing brain protein may be responsible for severe over-worry and fear

A little bit of learned fear is a good thing, keeping us from making risky, stupid decisions or falling over and over again into the same trap. But new research from neuroscientists and molecular biologists at USC shows that a missing brain protein may be the culprit in cases of severe over-worry, where the fear perseveres even when there's nothing of which to be afraid.

16 Jul 2013

FDA approves Gilotrif for patients with late stage non-small cell lung cancer

Companion test also approved to identify appropriate patients The U.S. Food and Drug Administration today approved Gilotrif (afatinib) for patients with late stage (metastatic) non-small cell lung cancer (NSCLC) whose tumors express specific types of epidermal growth factor receptor (EGFR) gene mutations, as detected by an FDA-approved test. Lung cancer is the leading cause of cancer-related death among men and women.

16 Jul 2013

Pharmaceuticals News and Research

Ensemble Therapeutics announces initiation of drug discovery collaboration with Alexion subsidiary

Kolltan signs research agreement with CHOP for novel therapeutic approaches for neuroblastoma

Quest Diagnostics completes sale of ibrutinib commercialization rights to Royalty Pharma

Inovio's electroporation technology enhances ability of DNA therapy to stimulate blood vessel growth

Mandate matters: Examining the relationship between the health law's employer and individual mandates

Creating, promoting foods containing angiogenesis is the new frontier in dietary health

TSRI scientists study 3-D structure of glucagon receptor for treatment of diabetes

Chemical compound from ocean microbe offers potential treatments for anthrax

Rexahn Pharmaceuticals signs license agreement with UMB for novel drug delivery platform

Adynxx receives FDA Fast Track designation for AYX1 Injection to treat chronic pain

Spectrum Pharmaceuticals enters into agreement to acquire Talon Therapeutics

First Edition: July 17, 2013

Sequella licenses Pfizer's exclusive worldwide rights to develop, commercialize sutezolid

The more you chew, the more energy you retain

OncoGenex completes enrollment in OGX-427 Phase 2 trial for treatment of metastatic bladder cancer

FDA accepts Iroko's submicron indomethacin NDA for treatment of acute pain in adults

Study identifies new therapeutic targets for Huntington's disease

Furiex Pharmaceuticals enrolls patient for Phase III clinical trial of eluxadoline for treatment of diarrhea

USC study shows missing brain protein may be responsible for severe over-worry and fear

FDA approves Gilotrif for patients with late stage non-small cell lung cancer

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence